Payment overview · 2025
General Payments
$407.98
22 reported records · 13 companies
Healthcare provider profile · identity verified
Michele T Edwards-Paschal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WARNER ROBINS, GA · NPI 1477565810
Verified facts
What the public records show
CMS Open Payments records show Michele T Edwards-Paschal, MD received $407.98 in general payments during 2025 across 22 reported records.
Lilly USA, LLC accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $92.41 | 22.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.32 | 10.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.31 | 9.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $39.34 | 9.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.08 | 8.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.38 | 7.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.16 | 5.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.87 | 4.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.77 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.30 | 4.5% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $17.91 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.03 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.10 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $407.98 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.44 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.31 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 117 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 457 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 292 | 76 |
| Lisinopril | Lisinopril | 241 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 53 |
| Gabapentin | Gabapentin | 224 | 58 |
| Losartan Potassium | Losartan Potassium | 215 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 54 |
| Omeprazole | Omeprazole | 185 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 49 |
| Potassium Chloride | Potassium Chloride | 160 | 45 |
| Ozempic | Semaglutide | 145 | 26 |
| Furosemide | Furosemide | 142 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 33 |
| Montelukast Sodium | Montelukast Sodium | 138 | 36 |
| Mounjaro | Tirzepatide | 134 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 36 |
| Metformin Hcl | Metformin Hcl | 123 | 37 |
| Alprazolam | Alprazolam | 118 | 31 |
| Jardiance | Empagliflozin | 117 | 29 |
| Simvastatin | Simvastatin | 114 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 23 |
| Carvedilol | Carvedilol | 100 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 31 |
| Trazodone Hcl | Trazodone Hcl | 93 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 89 | 26 |
| Farxiga | Dapagliflozin Propanediol | 89 | 18 |
| Famotidine | Famotidine | 87 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 19 |
| Eliquis | Apixaban | 82 | 18 |
| Metformin Hcl Er | Metformin Hcl | 82 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 26 |
| Mirtazapine | Mirtazapine | 81 | 26 |
| Sertraline Hcl | Sertraline Hcl | 80 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 28 |
| Donepezil Hcl | Donepezil Hcl | 67 | 17 |
| Ezetimibe | Ezetimibe | 65 | 20 |
| Lorazepam | Lorazepam | 65 | 15 |
| Glipizide Er | Glipizide | 62 | 15 |
| Spironolactone | Spironolactone | 62 | 19 |
| Tramadol Hcl | Tramadol Hcl | 61 | 17 |
| Synthroid | Levothyroxine Sodium | 60 | 17 |
| Meloxicam | Meloxicam | 58 | 21 |
| Atenolol | Atenolol | 57 | 15 |
| Memantine Hcl | Memantine Hcl | 56 | 11 |
| Glipizide | Glipizide | 55 | 15 |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Glimepiride | Glimepiride | 54 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 19 |
| Alendronate Sodium | Alendronate Sodium | 51 | 12 |
| Irbesartan | Irbesartan | 51 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | 12 |
| Felodipine Er | Felodipine | 50 | suppressed |
| Trulicity | Dulaglutide | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Allopurinol | Allopurinol | 46 | 15 |
| Telmisartan | Telmisartan | 46 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 20 |
| Methylprednisolone | Methylprednisolone | 39 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 27 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Estradiol | Estradiol | 33 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 28 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 26 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Nystatin | Nystatin | 29 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Linzess | Linaclotide | 28 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Ibuprofen | Ibuprofen | 27 | 11 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Finasteride | Finasteride | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Methimazole | Methimazole | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pindolol | Pindolol | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.98 · 22 records | Lilly USA, LLC | CAPVAXIVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, GARDASIL 9, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, Wegovy, XIFAXAN, Xelstrym, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error